地舒单抗与双膦酸盐治疗骨质疏松的随机对照试验荟萃分析
该荟萃分析纳入10项头对头随机对照试验共5361例低骨密度或骨质疏松成人患者,比较地舒单抗与双膦酸盐的疗效。结果显示地舒单抗在12和24个月时对腰椎、全髋和股骨颈骨密度的提升均显著优于双膦酸盐;仅在24个月时有一项研究显示地舒单抗较阿仑膦酸钠降低骨质疏松性骨折发生率。
要点
- 地舒单抗在12和24个月时提升腰椎、全髋和股骨颈骨密度均显著优于双膦酸盐。
- 12个月时骨折终点无差异,24个月时仅一项研究显示地舒单抗较阿仑膦酸钠降低骨折风险。
- 结论需更长期大样本纵向研究确认疗效差异。
核心结论
- 地舒单抗在12和24个月时对腰椎、全髋和股骨颈骨密度的提升显著优于双膦酸盐治疗。
- 仅一项研究显示地舒单抗较阿仑膦酸钠在24个月时降低骨质疏松性骨折发生率。
- 需要更长随访和大样本纵向研究确认疗效差异。
研究设计与样本
- 检索PubMed、Embase和Cochrane Library截至2018年11月,纳入比较地舒单抗与双膦酸盐的头对头随机对照试验。
- 纳入10项合格试验,共5361例低骨密度或骨质疏松成人患者。
- 采用随机效应模型进行荟萃分析。
主要发现
- 12个月时地舒单抗较双膦酸盐提升腰椎骨密度平均差1.42%(95%CI 0.95%至1.89%,P<0.001)。
- 12个月时全髋骨密度平均差1.11%(95%CI 0.91%至1.30%,P<0.001),股骨颈1.00%(95%CI 0.78%至1.22%,P<0.001)。
- 24个月时腰椎、全髋和股骨颈骨密度提升差异分别为1.74%(95%CI 1.05%至2.43%,P<0.001)、1.22%(95%CI 0.66%至1.77%,P<0.001)和1.19%(95%CI 0.65%至1.72%,P<0.001)。
- 12个月时骨折终点无差异,24个月时地舒单抗较阿仑膦酸钠降低骨质疏松性骨折发生率(RR 0.51,95%CI 0.27至0.97)。
临床怎么用
- 对于低骨密度或骨质疏松患者,地舒单抗在提升腰椎、全髋和股骨颈骨密度方面可能优于双膦酸盐。
- 骨折风险降低的证据主要来自与阿仑膦酸钠的单项研究比较,需结合患者具体情况选择治疗。
局限性
- 仅一项研究显示地舒单抗在24个月时降低骨质疏松性骨折发生率,骨折疗效证据有限。
- 需要更长随访时间和更大样本量的纵向研究确认疗效差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: It is uncertain which osteoporosis therapy is more effective: bisphosphonates or denosumab. OBJECTIVE: To determine whether denosumab therapy increases bone mineral density (BMD) and reduces fracture risk more so than bisphosphonates in patients with low BMD or osteoporosis. METHODS: The PubMed, Embase, and the Cochrane Library databases were searched through November 2018 for head-to-head, randomized, controlled trials comparing denosumab and bisphosphonates among adult patients with low BMD or osteoporosis. Random-effects models were used. RESULTS: We identified 10 eligible trials including 5361 participants. Denosumab increased BMD more than bisphosphonate at 12 months (mean difference, 1.42%; 95% CI, 0.95% to 1.89%; P < 0.001) at lumbar spine, 1.11% (95% CI, 0.91% to 1.30%; P < 0.001) at total hip, and 1.00% (95% CI, 0.78% to 1.22%; P < 0.001) at femoral neck. At 24 months, the respective increase differences were 1.74% (95% CI, 1.05% to 2.43%; P < 0.001), 1.22% (95% CI, 0.66% to 1.77%; P < 0.001), and 1.19% (95% CI, 0.65% to 1.72%; P < 0.001). There was no difference in fracture end point at 12 months, but denosumab had a lower osteoporotic fracture incidence than alendronate at 24 months (risk ratio, 0.51; 95% CI, 0.27 to 0.97). CONCLUSION: Denosumab improved BMD significantly more than bisphosphonate treatment at the lumbar spine, total hip, and femoral neck at 12 and 24 months. Only one study demonstrated greater osteoporotic fracture reduction with denosumab treatment. Longitudinal studies with longer follow-up and large sample size are needed to confirm the efficacy difference.
引用
- Lyu H, Jundi B, Xu C, et al. Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. 2019. PMID: 30535289. doi:10.1210/jc.2018-02236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。